文献
J-GLOBAL ID:201202241524783384
整理番号:12A0376424
トリプルネガティブ表現型は、dose-dense連続補助化学療法で治療した患者の有害予後値のものである:ギリシャ共同腫瘍学グループ(HeCOG)の無作為化第III相試験のコンテキストにおけるトランスレーショナルリサーチの分析
Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
著者 (26件):
SKARLOS P.
(Agios Savvas Cancer Hospital, Dep. of Radiotherapy, Athens, GRC)
,
CHRISTODOULOU C.
(Metropolitan Hospital, Second Dep. of Medical Oncology, Piraeus, GRC)
,
KALOGERAS K. T.
(Data Office, Translational Res. Section, Hellenic Cooperative Oncology Group, Athens, GRC)
,
KALOGERAS K. T.
(Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Medical Oncology, Papageorgiou Hospital, Thessaloniki, GRC)
,
ELEFTHERAKI A. G.
(Data Office, Section of Biostatistics, Hellenic Cooperative Oncology Group, Athens, GRC)
,
BOBOS M.
(Aristotle Univ. of Thessaloniki School of Medicine, Lab. of Molecular Oncology, Hellenic Foundation for Cancer Res. ...)
,
BATISTATOU A.
(Ioannina Univ. Hospital, Dep. of Pathology, Ioannina, GRC)
,
VALAVANIS C.
(Metaxas Cancer Hospital, Dep. of Pathology, Piraeus, GRC)
,
TZAIDA O.
(Metaxas Cancer Hospital, Dep. of Pathology, Piraeus, GRC)
,
TIMOTHEADOU E.
(Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Medical Oncology, Papageorgiou Hospital, Thessaloniki, GRC)
,
KRONENWETT R.
(Siemens Healthcare Diagnostics, Cologne, DEU)
,
KRONENWETT R.
(Sividon Diagnostics GmbH, Nattermann Allee 1, 50829, Cologne, DEU)
,
WIRTZ R. M.
(Siemens Healthcare Diagnostics, Cologne, DEU)
,
WIRTZ R. M.
(Stratifyer Molecular Pathology GmbH, Werthmannstrasse 1, 50935, Cologne, DEU)
,
KOSTOPOULOS I.
(Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Pathology, Thessaloniki, GRC)
,
TELEVANTOU D.
(Aristotle Univ. of Thessaloniki School of Medicine, Lab. of Molecular Oncology, Hellenic Foundation for Cancer Res. ...)
,
KOUTSELINI E.
(Metropolitan Hospital, Dep. of Pathology, Piraeus, GRC)
,
PAPASPIROU I.
(Alexandra Hospital, Dep. of Pathology, Athens, GRC)
,
PAPADIMITRIOU C. A.
(Univ. of Athens School of Medicine, Dep. of Clinical Therapeutics, Alexandra Hospital, Athens, GRC)
,
PECTASIDES D.
(Hippokration Hospital, Second Dep. of Internal Medicine, Oncology Section, Athens, GRC)
,
GOGAS H.
(Univ. of Athens Medical School, First Dep. of Medicine, Laiko General Hospital, Athens, GRC)
,
ARAVANTINOS G.
(Agii Anargiri Cancer Hospital, Third Dep. of Medical Oncology, Athens, GRC)
,
PAVLIDIS N.
(Ioannina Univ. Hospital, Dep. of Medical Oncology, Ioannina, GRC)
,
ARAPANTONI P.
(Metaxas Cancer Hospital, Dep. of Pathology, Piraeus, GRC)
,
SKARLOS D. V.
(Metropolitan Hospital, Second Dep. of Medical Oncology, Piraeus, GRC)
,
FOUNTZILAS G.
(Aristotle Univ. of Thessaloniki School of Medicine, Dep. of Medical Oncology, Papageorgiou Hospital, Thessaloniki, GRC)
資料名:
Cancer Chemotherapy and Pharmacology
(Cancer Chemotherapy and Pharmacology)
巻:
69
号:
2
ページ:
533-546
発行年:
2012年02月
JST資料番号:
D0065D
ISSN:
0344-5704
CODEN:
CCPHDZ
資料種別:
逐次刊行物 (A)
発行国:
ドイツ (DEU)
言語:
英語 (EN)